HDR Gateway logo
HDR Gateway logo

Bookmarks

National Cancer TRE

Population Size

Not reported

Years

2011

Associated BioSamples

None/not available

Geographic coverage

United Kingdom

England

Lead time

Not applicable

Summary

NHS Digitalā€™s Trusted Research Environment service for England provides approved researchers with access to essential linked, de-identified health data to answer COVID-19 related questions. TRE service provides researchers support on data access requests.

Documentation

NHS Digitalā€™s TRE service for England provides approved researchers with access to essential linked, de-identified health data to quickly answer COVID-19 related research questions. The TRE service provides researchers with support on data access requests, provision of data using the secure data platform the Data Processing Service (DPS) and help with analysis work. Approved research projects will help to guide national decision making and recommend potential interventions to reduce the severity of COVID-19 outcomes. NHSD are delivering the TRE service in partnership withĀ HDRUK.Ā Ā The shared objective is to provide rapid, safe and trustworthy access to data in a transparent way that accelerates the pace of quality research.

Dataset type
Health and disease
Dataset sub-type
Not applicable

Keywords

Cancer, Trusted Research Environment, COVID-19, Dataset, Episodes, Hospital, Diagnosis, Inpatients, Emergency, Operations, Admission, Finished Consultant Episode, Finished Admission Episode, FCE, FAE, Episode, Day Case, Ordinary, Elective, Waiting List, Planned, Main Speciality, Treatment Speciality, External Cause, Hospital Activity, HES, APC, DIGITRIALS, National Core Study, NCS, Accident, A&E, A&E Department, Major Injuries, Minor Injuries, Urgent Care, Arrival Method, Ambulance, A&E Waiting Time, Initial Assessment, Time in A&E, Re-attendance, Unplanned Investigation, Treatment, Outpatients, Appointment, Attendance, Did Not Attend, DNA, Cancellation, Attendance Type, Procedure, COVID-19 Hospitalisation in England Surveillance System, ICU, High Dependency, HOSPITALISATION, TESTING, LABORATORY, RISK, OUTCOME, TREATMENT, Deaths, GRO, Deceased, English Deaths, Registered Deaths, England Deaths, ONS

Provenance

Source of data extraction
EPR
Collection source setting
Clinic, Primary care - Clinic, Secondary care - Accident and Emergency, Secondary care - Outpatients, Secondary care - In-patients, Services, Community, Prescribing - Community pharmacy
Patient pathway description

Enumerating the impact of COVID-19 on cancer pathways: a robust evaluation of the NHS Digital Trusted Research Environment (TRE).

We will delineate the precise impact of the COVID 19 pandemic on cancer systems and cancer patients. This requires access to both historical data (pre 2020) and near real-time data on patients referred with (i) a suspicion of cancer and (ii) those diagnosed with and/or managed for cancer. Our emphasis is on data on cancer referral

, cancer diagnosis, cancer treatment and cancer outcomes, examining the impact of age, ethnicity, deprivation,

comorbidity and concurrent medication.

We will examine the effects of COVID-19 on: ā€¢ Cancer referral (including those which lead to a cancer diagnosis and those where cancer is excluded) ā€¢ Cancer diagnosis (including date

, tumour site, stage, grade,

morphology and key molecular/genetic/ phenotype) ā€¢ Cancer treatment (including surgical procedures

,

chemotherapy/targeted therapy and radiotherapy) ā€¢ Clinical trial activity including recruitment to and active treatment within trials ā€¢ Outcomes (including both hospital admission

, survival,

mortality and cause of death) ā€¢ COVID status (including COVID testing (Pillar 1&2) and results

,

acute hospitalisation and related direct COVID deaths in cancer patients). We will also examine the interaction and impact of other factors including ā€¢ Age ā€¢ Ethnicity ā€¢ Social deprivation (IMD quintile) ā€¢ Comorbidity (based on both hospital and primary care data) ā€¢ Concurrent medication (including both hospital and primary care data) ā€¢ Geography including rurality and health care region ā€¢ Rates of COVID infection

,

hospitalisation and death in discrete health care regions

We will compare activity from 2019 and 2020 but to include patients diagnosed with cancer at any time before then.

Image contrast
Not stated
Biological sample availability
None/not available

Structural Metadata

Details

Publishing frequency
Continuous
Version
2.0.0
Modified

08/10/2024

Distribution release date

01/03/2021

Citation Requirements
DATA-CAN The HDR UK Hub for Cancer

Coverage

Start date

01/01/2011

Time lag
1-2 months
Geographic coverage
United Kingdom, England
Maximum age range
150
Follow-up

10 Years

Accessibility

Language
en
Controlled vocabulary
OPCS4, SNOMED CT, DM+D, NHS NATIONAL CODES, ODS, ICD10
Format
text/json, text/xml, text/csv

Data Access Request

Dataset pipeline status
Not available
Time to dataset access
Not applicable
Access method category
Varies based on project
Access service description

Organisations and individuals wanting to use certain kinds of data need to show they meet strict data governance standards by completing the NHS Digital DARS application process.

The DARS team makes sure we only supply sensitive patient level data to organisations that look after it according to Information Governance (IG) requirements, and use it to improve health and care services.

Jurisdiction
GB-ENG
Data use limitation
General research use
Data use requirements
Collaboration required, Institution-specific restrictions, Project-specific restrictions, User-specific restriction
Data Controller

University of Leeds Leeds Teaching Hospital Trust

Data Processor

University of Leeds Leeds Teaching Hospital Trust

Dataset Types: Health and disease


Collection Sources: No collection sources listed

Relationships: